KYOWA KIRIN CO. LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,630 JPY | +0.23% |
|
+0.80% | +10.97% |
| Apr. 08 | U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease | RE |
| Apr. 03 | Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March | MT |
| Sales 2024 * | 471B 2.97B | Sales 2025 * | 483B 3.05B | Capitalization | 1,407B 8.88B |
|---|---|---|---|---|---|
| Net income 2024 * | 66.51B 420M | Net income 2025 * | 72.93B 460M | EV / Sales 2024 * | 2.29 x |
| Net cash position 2024 * | 330B 2.08B | Net cash position 2025 * | 361B 2.28B | EV / Sales 2025 * | 2.17 x |
| P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
19.1
x | Employees | 5,974 |
| Yield 2024 * |
2.21% | Yield 2025 * |
2.31% | Free-Float | 45.89% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.23% | ||
| 1 week | +0.80% | ||
| Current month | -2.25% | ||
| 1 month | -4.00% | ||
| 3 months | +12.47% | ||
| 6 months | +11.87% | ||
| Current year | +10.97% |
1 week
2 603.00
2 682.50
1 month
2 578.002 762.00
Current year
2 266.503 009.00
1 year
2 266.503 075.00
3 years
2 266.504 240.00
5 years
1 674.004 240.00
10 years
1 094.004 240.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 86-03-31 | |
Masashi Miyamoto
PSD | President | 64 | 85-03-31 |
| Chief Tech/Sci/R&D Officer | 62 | 10-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takashi Oyamada
BRD | Director/Board Member | 68 | 21-02-28 |
Yoshihisa Suzuki
BRD | Director/Board Member | 68 | 22-02-28 |
| Director/Board Member | 66 | 08-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.22% | 15 M€ | +7.34% | ||
| 0.44% | 11 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 2,630 | +0.23% | 857,100 |
| 24-04-25 | 2,624 | -1.09% | 875,000 |
| 24-04-24 | 2,653 | -0.09% | 910,300 |
| 24-04-23 | 2,656 | -0.02% | 1,118,900 |
| 24-04-22 | 2,656 | +1.80% | 1,077,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
2,630
JPY
Average target price
3,067
JPY
Spread / Average Target
+16.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.97% | 8.94B | |
| +5.31% | 70.44B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- 4151 Stock
